drugset / Trial / NCT05840952

A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

NCT05840952

Phase 1 Completed 90 enrolled Aligos Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multi-part study of ALG-097558 to evaluate safety, tolerability, pharmacokinetics and drug-drug interaction potential after single and multiple doses in healthy volunteers

Timeline

Start
2023-07-04
Primary completion
2024-04-29
Completion
2024-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ALG-097558 Unknown Oral
Subject Carbamazepine Small molecule Oral
Subject Itraconazole Small molecule Oral
Subject Midazolam Small molecule Oral

Indications